# A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

> **NCT00874887** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 66 (actual)

## Conditions studied

- Anti-biotic Resistance

## Interventions

- **DRUG:** moxifloxacin 0.5% HCI ophthalmic solution
- **DRUG:** gatifloxacin ophthalmic solution 0.3%

## Key facts

- **NCT ID:** NCT00874887
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2009-09
- **Final completion:** 2009-10
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2011-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00874887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00874887, "A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00874887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*